Gunderson Dettmer Releases Q3 2024 Valuation Report

In Q3 2024, Gunderson Dettmer represented technology and life sciences companies in 288 venture capital financings, raising over $10 billion and valuing these companies at over $60 billion.  

Gunderson Dettmer’s Q3 2024 Valuation Report analyzes valuation data collected from financing transactions (ranging from pre-seed SAFE/convertible note rounds through Series D equity financings) that closed in Q3 and in which the firm represented either the company or an investor. This report focuses on valuations for technology companies and excludes financings for life sciences companies (as well as some outliers) from our dataset to avoid presenting skewed valuations. In the upcoming 2024 Valuation Report, we will offer a special section focused on valuations for life sciences companies. 

The report presents data from Q3 2020 to the current quarter to provide historical context and offers analysis of market trends in venture financing covering valuations, amounts raised and deal volume. In addition, Gunderson corporate partners provide insights to contextualize the data based on their observations from negotiating deals on behalf of the firm’s clients. According to Pitchbook, Gunderson partners have negotiated more venture financings than any other law firm for the past decade.  

Read the full report here. 

Contributors:

Hozefa Botee, Corporate & Securities Partner, New York 

Laura Stoffel, Corporate & Securities Partner, Boston 

Mike Heath, Corporate & Securities Partner, Los Angeles

Greg Volkmar, Corporate & Securities Partner, New York